PDSB - PDS Biotechnology Corp (PDSB) - PDS0101 Triple Combination Data To Be Presented At ASCO

Phase 2 Triple Combination Study Data To Be Presented At ASCO. PDS Biotech will be making two data presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting, scheduled for June 3-7. A poster presentation of preliminary data from the Phase 2 Triple Combination trial is scheduled for June 5. This trial tests PDS0101 in combination with two immune modulating drugs in HPV-associated cancers.Trial Summary. The study enrolls patients with advanced HPV16-positive cancers who have failed prior therapy. Patients received a combination of PDS0101 with a tumor-targeting IL-12 (M9241), and bintrafusp alfa, a bifunctional checkpoint inhibitor (PD-L1/ TGF-beta). This regimen is intended to allow the immune system to recognize tumors and to stimulate a strong immune response against them. Read More >>